Tablet Blister Packaging: Process Control, Validation and Compliance

An auditor looking at tablet blister packaging asks a narrow set of questions. Can you show the line was qualified for this material and this format? What are the critical process parameters, how were the ranges established, and what happens when one drifts? How do you know every pocket contained exactly one tablet? How do you know the seal held?

Those questions are answerable only if the validation work was done properly in the first place, and if the in-process controls generate evidence rather than reassurance. This article sets out what good looks like across qualification, process control, inspection, documentation and release for solid oral dose.

It assumes the material specification is already settled. Formats and barrier films are covered separately in this series.

Qualifying a tablet blister packaging line
Qualification for tablet blister packaging follows the standard sequence, applied to a specific combination of machine, tooling, forming film, lidding foil and product.

Design qualification confirms the machine and change parts are specified for the intended formats: pocket geometry, index length, web width, feeder type, coding and inspection systems.

Installation qualification documents that the equipment as delivered matches the specification, that utilities are correct, that calibration certificates exist for every instrument measuring a critical parameter, and that software versions are recorded.

Operational qualification challenges the machine across its intended operating ranges without product: heating and sealing zones proven against calibrated references, temperature uniformity across the tooling, alarms and interlocks tested, inspection reject mechanisms verified, and worst-case settings exercised.

Performance qualification runs the actual product and materials at production speed, normally across three consecutive batches, to demonstrate that the process delivers conforming packs consistently. This is where seal strength, fill accuracy, coding legibility and rejection rates are proven, and where the operating ranges written into the batch record are confirmed.

Change control then governs anything that moves afterwards: a new film supplier, a different lidding foil lacquer, a tooling modification or a speed increase all require an assessment and, often, requalification.

Critical process parameters
Four parameter groups do most of the work.

Forming temperature. The film must soften enough to draw into the die without thinning excessively at the pocket corners. Too cold and pockets are incompletely formed or the film cracks. Too hot and the wall thins, which quietly degrades barrier performance at exactly the point where the pack is thinnest. Cold-form aluminium removes this parameter and replaces it with draw depth limits.

Sealing temperature, pressure and dwell. The three interact. A shorter dwell at higher speed needs more heat or more pressure to activate the same lacquer. Ranges are established at OQ and confirmed at PQ, and the batch record should state a validated window rather than a single set point.

Registration and index. The web must advance by exactly one pocket pitch so that pockets sit under the feeder, the print sits over the correct pocket, and the cut falls on the flange rather than through a pocket. Registration failure on a calendarised pack is a patient safety defect.

Feeder settings and line speed. Vibration, brush position and channel geometry affect whether pockets fill reliably and whether tablets chip. Friable products often set the practical speed limit for the whole line.

In-process controls and inspection
Pocket fill verification
Every pocket must be checked before the lidding foil closes it, because once sealed, the defect is only detectable by destructive test. Camera systems inspect each pocket for presence, count, orientation and, for many products, colour and dimension, and reject the affected card downstream. Central Pharma runs 100% AI inspection, which extends the same principle to print and pack presentation.

Manual checks sit alongside the automated ones: operator checks against a defect library, and challenge tests at the start and end of each run confirming that the reject mechanism diverts a seeded defect.

Seal integrity and leak testing
Seal integrity is verified by a combination of destructive and non-destructive methods, typically at defined intervals through the batch.

Dye ingress testing places blister cards in a coloured solution under vacuum, then releases the vacuum and examines the pockets for dye penetration. It is cheap, sensitive and destructive. Vacuum decay and pressure decay methods measure whether a sealed pack holds a differential and are non-destructive, so they suit higher sampling frequencies. Seal strength is checked separately by peel testing, which tells you whether the seal is over-sealed and brittle as well as whether it is weak.

Whichever method is used, the acceptance criteria must be tied back to what was demonstrated at qualification, and the sampling plan must be justified in the validation documentation rather than chosen by habit.

Line clearance, reconciliation and documentation
Line clearance is the discipline that prevents mix-ups. Before a batch starts, the line and its surroundings are cleared of all previous product, film, foil, cartons, leaflets and printed materials, and the clearance is signed by a second person. Waste bins, reject chutes, machine guarding and the underside of feeders are all part of it, because that is where stray tablets and offcuts survive.

Reconciliation closes the loop at the end. Tablets issued against tablets packed, rejected and destroyed; foil and film issued against used and returned; printed components issued against applied and destroyed. Discrepancies outside defined limits are investigated before the batch can proceed. For controlled drugs the requirement is stricter still, with witnessed destruction and register entries.

The batch record carries all of it: materials and their release status, equipment identity, set points against validated ranges, in-process check results, deviations and their assessment, reconciliation and the sign-offs. Under GMP this documentation supports the Qualified Person's certification of the batch, and no batch reaches the market without it. GMP governs everything up to and including QP certification; GDP takes over for storage and distribution afterwards.

Labelling requirements specific to blisters
The Human Medicines Regulations 2012, Part 13, sets the statutory packaging and labelling requirements for UK packs, and information must be printed directly onto the packaging rather than over-labelled.

For blisters specifically, MHRA best practice guidance is clear that the product name and strength should be repeated over each pocket, or at frequent intervals along the foil, so that a partly used blister remains identifiable. Critical information should be grouped, the route stated positively, and colour should not be the sole means of distinguishing strengths. Look-alike and sound-alike risk is assessed at artwork stage, not discovered on the line.

Stability and shelf life
The pack is part of the product's stability profile. Shelf life is granted on the basis of stability data generated in the proposed container closure system, so a change of forming film, lidding foil or seal specification is a change to the licensed pack. That is why material substitutions late in a project are expensive: they can invalidate the data supporting the expiry date.

Key takeaways:

• Qualify the line as a combination of machine, tooling, materials and product, not as a machine alone, and control changes to any element afterwards.
• Forming temperature, sealing temperature/pressure/dwell, registration and feeder settings are the parameters that decide pack quality.
• Verify fill before sealing, because after sealing the only detection route is destructive testing.
• Combine destructive dye ingress with non-destructive decay methods for seal integrity, with sampling justified in the validation file.
• Repeat product name and strength over each blister pocket in line with MHRA best practice, and treat material changes as changes to the licensed pack.

Talk to Central Pharma about tablet blister packing
Central Pharma has packed for the pharmaceutical, medical device, cell and gene therapy and healthcare sectors from Bedford since 2006, under an MHRA MIA and WDA(H), with ISO 9001, ISO 13485, a dedicated QA team and three Qualified Persons releasing product to more than 60 countries. Tablet blister packaging runs with 100% AI inspection and real-time data, with secondary packing, serialisation and QP release on the same site. To discuss qualification, technical transfer or a validation timeline, get in touch.

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news